
Supplemental Table I: The list of genes containing m ⁶ A sites that were hypomethylated by
METTL3 knockdown under OS


	OS_siCtrl OS_siMETTL3													
Chr	Start	End	-log10(P-	Log2 Fold	Strand	Gene	Chr	Start	End	-log10(P-	Log2 Fold	Strand	Gene Featur	Fold
chr8	141,194,251	141,194,264	value) 22.661	Change 5.583	+	DENND3	obr®	141,194,270	141,194,353	value) 31.600	Change 3.451	+	e DENND3 3'UTR	0.228
chr12	1,490,575	1,490,608	46.544	5.103	+	ERC1		1,490,575	1,490,602	15.809	3.034	+	ERC1 3'UTR	0.228
chr8	91,960,419	91,960,437	37.744	5.712	-	RUNX1T1	chr8	91,960,431	91,960,473	11.099	3.968		RUNX1T1 CDS	0.230
chr7	150,573,229	150,573,238	27.127	4.665	+	GIMAP4	chr7	150,573,244	150,573,289	5.540	3.017	+	GIMAP4 3'UTR	0.319
chr9	131,260,675	131,260,760	30.905	4.711	-	FAM78A		131,260,556	131,260,616	5.262	3.111	-	FAM78A 3'UTR	0.330
chr11	35,619,499	35,619,508	26.062	4.862	+		chr11	35,619,350	35,619,384	31.883	3.321	+	FJX1 CDS	0.344
chr8	27,672,631	27,672,668	31.254	5.151	+	SCARA3	chr8	27,672,678	27,672,700	10.747	3.633	+	SCARA3 3'UTR	0.349
chr20	50,891,296	50,891,302	57.548	4.631	-	ADNP	chr20	50,891,259	50,891,274	22.040	3.128	-	ADNP 3'UTR	0.353
chr3	42,536,959	42,537,017	32.324	5.794	+	VIPR1	chr3	42,537,258	42,537,316	11.809	4.367	+	VIPR1 3'UTR	0.372
chr7	44,883,034	44,883,039	67.183	6.007	-	PURB	chr7	44,883,003	44,883,040	85.366	4.674	-	PURB 3'UTR	0.397
chr19	52,612,852	52,612,875	17.752	4.427	-	ZNF83	chr19	52,612,881	52,612,947	7.246	3.139	-	ZNF83 3'UTR	0.410
chr12	12,330,321	12,330,342	78.319	4.666	-	MANSC1	chr12	12,330,482	12,330,550	28.095	3.397	-	MANSC1 CDS	0.415
chr8	17,645,678	17,645,682	55.911	4.966	-	MTUS1	chr8	17,645,683	17,645,700	28.793	3.727	-	MTUS1 3'UTR	0.424
chr17	5,501,517	5,501,523	12.538	4.941	-	NLRP1		5,501,475	5,501,527	8.537	3.708	-	NLRP1 3'UTR	0.426
chr13	109,756,093	109,756,163	31.861	6.246	-		chr13	109,755,594	109,755,638	24.286	5.018	-	IRS2 3'UTR	0.427
chr1	64,692,106	64,692,127	14.129	4.820	+	CACHD1		64,691,951	64,691,977	7.521	3.597	+	CACHD1 3'UTR	0.428
chr3	48,158,817	48,158,827	52.498	6.053	-	CDC25A		48,158,828	48,158,837	30.830	4.832	-	CDC25A 3'UTR	0.429
chr6	138,424,226	138,424,240	400.000	5.264	-	NHSL1	chr6	138,424,165	138,424,173	52.901	4.062	-	NHSL1 CDS	
chr2	236,165,632	236,165,672	13.168	4.655	-	GBX2		236,165,564	236,165,613	15.962	3.473	-	GBX2 3'UTR	0.441
chr19	16,893,950	16,893,985	13.578	4.355	-+	CPAMD8		16,894,292	16,894,334	4.289	3.266	-	CPAMD8 CDS SLC25A25 3'UTR	
chr9 chr21	128,107,706 37,512,439	128,107,792 37,512,446	47.431 56.790	4.580 5.045	+	SLC25A25 DYRK1A	chr9	128,107,476 37,512,447	128,107,534 37,512,509	15.254 400.000	3.545 4.069	+	DYRK1A CDS	0.488
chr10	100,548,243	100,548,321	49.926	4.169	+	HIF1AN		100,548,202	100,548,322	33.677	3.211	+	HIF1AN 3'UTR	0.509
chr6	12,120,476	12,120,527	20.548	3.934	+	HIVEP1	chr6	12,121,101	12,121,114	8.892	3.003	+	HIVEP1 CDS	0.525
chr4	20,619,406	20,619,413	18.667	4.103	+	SLIT2		20,619,196	20,619,274	18.912	3.177	+	SLIT2 3'UTR	0.526
chr19	40.033.505	40.033.610	11.023	4.494		ZNF780B		40,033,502	40.033.619	9.793	3.594		ZNF780B 3'UTR	0.536
chr12	50,986,944	50,986,954	14.508	4.233	-	SLC11A2		50,986,954	50,987,003	10,784	3.361		SLC11A2 3'UTR	0.546
chr16	20,735,093	20,735,102	49.917	5.425	-	THUMPD1	chr16	20,735,103	20,735,121	35.148	4.553	-	THUMPD1 3'UTR	0.547
chr15	90,229,379	90,229,429	12.290	4.643	+	SEMA4B	chr15	90,229,378	90,229,391	14.470	3.848	+	SEMA4B 3'UTR	0.576
chr1	183,926,300	183,926,337	30.423	3.909	+	RGL1	chr1	183,926,325	183,926,338	12.829	3.115	+	RGL1 3'UTR	0.577
chr1	64,692,127	64,692,203	17.537	4.684	+	CACHD1	chr1	64,691,977	64,692,027	10.374	3.973	+	CACHD1 3'UTR	0.611
chr1	25,567,560	25,567,571	49.834	5.119	+	LDLRAP1	chr1	25,567,582	25,567,662	47.335	4.416	+	LDLRAP1 3'UTR	0.614
chr9	107,485,495	107,485,551	22.813	4.174	-	KLF4	chr9	107,485,546	107,485,578	25.326	3.483	-	KLF4 3'UTR	0.619
chr8	41,932,095	41,932,128	21.374	4.449	-	KAT6A	chr8	41,931,910	41,931,981	13.533	3.800	-	KAT6A 3'UTR	0.638
chr8	13,085,663	13,085,671	59.849	4.667	-	DLC1	chr8	13,085,676	13,085,682	400.000	4.075	-	DLC1 3'UTR	0.664
chr6	107,068,577	107,068,644	6.504	4.256	-	BEND3	chr6	107,068,444	107,068,507	8.048	3.731	-	BEND3 3'UTR	0.695
chr9	4,860,420	4,860,445	6.742	3.565	+	RCL1	chr9	4,860,419	4,860,471	14.365	3.053	+	RCL1 3'UTR	0.701
chr16	25,239,375	25,239,406	7.507	4.259	-	ZKSCAN2		25,239,326	25,239,415	12.385	3.811	-	ZKSCAN2 3'UTR	0.733
chr7	129,212,462	129,212,517	22.898	4.937	+	SMO		129,212,460	129,212,518	11.643	4.514	+	SMO 3'UTR	0.746
chr8	23,117,106	23,117,112	20.718	4.162	+	TNFRSF10C	chr8	23,117,104	23,117,147	26.657	3.823	+	TNFRSF10C 3'UTR	0.791
chr19	2,477,946	2,477,959	25.701	3.579	+			2,477,945	2,477,957	400.000	3.259	+	GADD45B 3'UTR	0.801
chr6	137,878,690	137,878,768	7.258	4.194 5.142	+++	TNFAIP3 EGFR		137,878,705	137,878,773	13.204	3.877	+	TNFAIP3 CDS EGFR 3' UTR	0.803
chr7	55,206,343 239,052,438	55,206,372 239,052,520	31.308 7.334	5.142 4.390	+	HDAC4	chr2	55,206,372 239,052,525	55,206,440 239,052,609	41.353 9.673	4.944 4.215	+	HDAC4 3'UTR	0.872
chr2 chr11	6,391,889	6,391,894	40.787	4.390	+	SMPD1		6,391,903	6,391,965	9.673	3.382	- +	SMPD1 CDS	0.886
CHITT	0,391,669	0,391,094	40.787	3.423	+	SWP/D1	CHILL	0,391,903	0,391,905	47.744	3.362	+	SWPD1 CDS	0.972

Gene Name	Gene #	Primer name	Sequence	Tm	Product size	
Metti3	NM_019852.4	hMettl3QF	TGGGGGTATGAACGGGTAGA	60	149	RT-PCR
		hMettl3QR	TGGTTGAAGCCTTGGGGATT			
Ythdf1	NM_017798	hYthdf1QF	GACTTTGAGCCCTACCTTACTG	55	131	RT-PCR
		hYthdf1QR	GACCACGGAGCCTCATTG			
Ythdf2	NM_016258	hYthdf2QF	TCTGGAAAAGGCTAAGCAGG	57	145	RT-PCR
		hYthdf2QR	CTTTTATTTCCCACGACCTTGAC	57	1	
Ythdf3	NM_152758	hYthdf3QF	TAGGTGTTGTACCTGTCAGT	55	122	RT-PCR
		hYthdf3QR	ACGTCCATTCTTCAGATTCC	55	1	
KLF4	NM_004235.6	hKlf4QF	CCGCTCCATTACCAAGAGCT	60	76	RT-PCR
		hKlf4QR	ATCGTCTTCCCCTCTTTGGC			
NLRP1	NM_033004.4	hNLRP1_F	GTTCAGGGATGCTGGAAATA	55	207	RT-PCR
		hNLRP1_R	CTGGAGGGATCAGAGTAGTT	55		1
NLRP1	NM_033004.4	hNLRP1_pos1F	TCTTCCAGTGTCTTGCAGGC	60	200	meRIP-qPCR
		hNLRP1_pos1R	GATGTTCCCAGGTGGTGAGG	60	1	
		hNLRP1_pos2F	CTGAAGGAGACCCATCCTCAC	57	139	meRIP-qPCR
		hNLRP1_pos2R	ACCCAAAGAAGGGTCAGCCA	57	1	
		hNLRP1_pos3F	AGCATCTCAGGGAATGTCCA	60	160	meRIP-qPCR
		hNLRP1_pos3R	TGACACAGCCAGAGGCAAATG	60]	
KLF4	NM_004235.6	hKlf4_pos1F	AAGAAGAAGGATCTCGGCCA	60	155	meRIP-qPCR
		hKlf4_pos1R	CATGTCAGACTCGCCAGGTG	60		
		hKlf4_pos2F	ACCTTACCACTGTGACTGGG	60	131	meRIP-qPCR
		hKlf4_pos2R	ACCTGGAAAATGCTCGGTCG	60	1	
		hKlf4_pos3F	TGGTCAAGTTCCCAACTGAGTC	60	181	meRIP-qPCR
		hKlf4_pos3R	TCCACAACTTCCAGTCACCC	60]	1
M13		M13_F	TGTAAAACGACGGCCAGT	55		RIP
		M13_R	CAGGAAACAGCTATGAC	55]	
Mettl3/APPA		Mettl3/APPA-F	gcagttgtgatggctgccccacccgcggatattcacatggaa	55		site-directed
		Mettl3/APPA-R	ttccatgtgaatatccgcgggtggggcagccatcacaactgc	5		mutagenesis

Supplemental Table II: Primer information


Supplemental Figure 1






Supplemental Figure 1: Comparison of METTL3 expression in the endothelium of the inner AA and the outer AA from wild-type control mice. (A) Schemes showing the regions of thoracic aorta (TA) and aortic arch (AA). (B) Specificity validation of m6A dot blot. (C) Shear pattern- and time-dependent increase of METTL3 mRNA and (D) protein expression over a 48-hour time course. (E) Left: En face immunofluorescence staining showing the expression of METTL3 in arterial endothelium of TA and outer and inner parts of AA. Right: quantification showing mean fluorescence intensity values relative to TA with SD error bars. (F-G) Immunohistochemistry of METTL3 protein expression in the endothelium of the outer AA (Panel F, Upper) and the inner AA (Panel F, Lower) from control untreated C57BL/6 mice. (H) Specificity validation of METTL3 immunofluorescence.

Supplemental Figure 2




Supplemental Figure 2: METTL3 as a mediator of the pro-atherogenic process in ECs in response to disturbed flow. (A) Schemes showing the sequence for wild-type METTL3 and its catalytic mutant form, METTL3 APPA. (B~C) LCMS analysis showing the m6A modification of mRNA with or without TNF- α stimulation in both HUVECs (Panel B) and HAECs (Panel C). (D) Representative images of monocyte adhesion on TNF- α -stimulated HUVECs with or without Mettl3 knockdown. (E) Scheme showing METTL3 as a mediator of the pro-atherogenic inflammatory effects in ECs subjected to disturbed flow.



Supplemental Figure 3: Involvement of METTL3-hypermethylated genes in atherosclerosis. (A)The pie chart depicts the relative frequency of peaks in OS-treated ECs with or without *Mettl3* knockdown. The pie chart depicts the relative frequency of peaks that map to each feature type, with a peak log2 fold enrichment \geq 3 and p-value \leq 0.001. (B) The list of genes affected by METTL3-knockdown under OS. (C) The eCLIP abundance of NLRP1 and KLF4 among PS-treated cells, OS-treated cells with either siCtril or siMETTL3.

Supplemental Figure 4

Suppl Figure 4



NLRP1-WT: CCTCACCTCATTATGGAACTCTGGGAGAAGGGCAGCAAAAAGGGACTCC NLRP1-mut: CCTCCCCTCATTATGGAACTCTGGGAGAAGGGCAGCAAAACGGGACTCC KLF4-WT: AATCCGACTTGAATATTCCTGGACTTACAAAATGCCAAGGGGG KLF4-mut: AATCCGACTTGAATATTCCTGGCCTTACAAAATGCCAAGGGGG

Supplemental Figure 4: The plasmid design of NLRP1 and KLF4 RNA fragments with either wildtype (WT) or mutated (mut) m6A sites.